QuarkMed
- Company typePrivate
- Founded2011
- HeadquartersFengtai, China
- Headcount11–50
- GTM typeB2B
- OfferingServices
QuarkMed firmographics
Firmographics- Name
- QuarkMed
- Legal name
- 北京夸克医药科技有限公司
- Website
- https://qmcro.com
- Company type
- Private
- Founded year
- 2011
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
QuarkMed industry classification
Industry- Product category
- Clinical Research Organization (CRO) Services
- NAICS
- Research and Development in the Physical, Engineering, and Life Sciences (54171)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Clinical CROs (Phase I–IV) (HLAGAAAA)
- akta.pro secondary industries
- Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL), Clinical Data Management, Biostatistics & Statistical Programming CROs (HLAGAAAF), Patient Recruitment, Site Feasibility & Trial Enablement CROs (HLAGAAAI), Pharmacovigilance, Risk Management & Medical Affairs CROs (HLAGAAAH), Real-World Evidence (RWE), HEOR & Epidemiology CROs (HLAGAAAK), Analytical Development & QC Testing (Release/Stability/Potency) (HLAGAGAF)
Keywords
Where QuarkMed is headquartered
LocationHeadquarters
- HQ city
- Fengtai
- HQ country
- China
- HQ region
- Asia
Offices8 records
Markets served
QuarkMed business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Clinical CRO Service Fees: QuarkMed generates revenue through comprehensive clinical research organization (CRO) service fees. Services span the entire drug and medical device development lifecycle including drug and device clinical research, data management and statistical analysis, SMO, biological testing, imaging, and international registration services for Europe, Australia, and North America markets. Fees are typically structured as project-based professional service contracts tailored to client needs.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
QuarkMed product offering
Product offeringCore offering
QuarkMed is a clinical Contract Research Organization (CRO) providing full-service clinical research solutions for pharmaceutical and medical device companies. Services span the entire drug and device development lifecycle—from registration declaration and clinical operations through post-marketing research—covering therapeutic areas including nuclear medicine, oncology, cell and gene therapy (CGT), psychiatry/neurology, respiratory, medical devices, and bioequivalence, with international registration services for China, Europe, Australia, and North America markets.
Product overview
QuarkMed is a professional clinical CRO services company founded in 2011, offering a comprehensive platform of clinical research services. The portfolio consists of core service modules — including drug and medical device clinical research, nuclear medicine, oncology, cell and gene therapy (CGT), data management and biostatistics, SMO (site management), medical affairs, pharmacovigilance, third-party audit, and pharmacoeconomic evaluation — supplemented by AI-enabled platforms such as the medical big data AI platform and quantitative pharmacology services. The company also provides international registration services covering China, the US, Europe, and Australia. Key sub-brands include Heyue Medical (禾玥医药), a nuclear medicine-focused SMO subsidiary, and Linddao Medical (临道医疗), a medical device CRO subsidiary. All services are unified under a '陪伴成长，成就客户' philosophy, covering the full drug and device lifecycle from pre-clinical to post-marketing.
Differentiator
Problem solved
Functional benefit
Brands
- 禾玥医药: 夸克医药旗下专注于核药领域的SMO，提供核药临床现场管理的专业服务。
- 临道医疗
Products and services
- Drug and Medical Device Clinical Research Service (药物与器械临床研究服务) End-to-end clinical research services for drugs and medical devices, covering the full development lifecycle from registration declaration through post-marketing studies, for pharmaceutical and medical device companies.
- Nuclear Medicine Clinical Research Service (核医学临床研究服务) Specialized nuclear medicine clinical research services for radioactive drugs, radiation therapy and imaging, and isotope tracing products, providing registration, clinical operations, and commercialization support to radiopharmaceutical developers.
- Oncology Clinical Research Service (肿瘤临床研究服务) Oncology clinical research services with specialized teams in registration declaration, clinical medicine, and biostatistics, integrated with the AI data platform to accelerate patient recruitment and follow-up.
- Cell and Gene Therapy (CGT) Clinical Research Service (细胞与基因治疗临床研究服务) Cell and gene therapy clinical research covering the full IND-to-NDA registration and clinical trial process, with established partnerships with over 100 CGT-related organizations.
- Data Management and Statistical Analysis (数据管理与统计分析) Standardized data management and statistical analysis services aligned with international standards, providing flexible and accurate solutions for clinical trial data needs.
- SMO Service - Site Management Organization (SMO服务) Clinical trial site management services assisting research institutions with non-medical professional operations, including subject recruitment, biological sample management, and quality control.
- Medical Big Data AI Platform (医疗大数据AI平台) AI-powered medical big data platform based on tumor multi-omics data and artificial intelligence algorithms, enabling patient recruitment, screening, and improved clinical study success rates.
- Quantitative Pharmacology Service (定量药理服务) Specialized quantitative pharmacology services with an independent professional team providing clinical study guidance, including study design, dose prediction, and clinical development strategy.
- International Registration Service (国际注册服务) International drug registration services covering China, the USA, Europe, Australia and other markets, providing feasibility assessment, regulatory strategy, clinical trial support, and full-process registration application services.
- Clinical Operations (临床运营) Clinical trial operations including feasibility assessment, clinical strategy, project management, and clinical monitoring across trial design, site selection, data management, and reporting.
- Drug and Device Registration Declaration (药械注册申报) Drug and medical device registration declaration services including strategy formulation, NDA document preparation, IND applications for China-US dual filing, CDE communication, and full registration process management.
- Pharmacovigilance (药物警戒) Drug safety monitoring services covering the full drug lifecycle including safety management plans, case report management, risk control plans, SAE consistency checks, and security update reports.
- Third-Party Audit (第三方稽查) Third-party clinical trial audit services ensuring GCP compliance, including BE/PK/Phase I trial audits, site audits, TMF audits, SOP establishment, and data management audits.
- Medical Affairs and Strategy (医学事务和策略) Medical affairs and strategy services including product development strategy consulting, medical writing and review, medical evaluation and monitoring, and risk identification and management.
- Post-Marketing Research (上市后研究) Post-marketing research services including Phase IV clinical trials, drug safety/effectiveness studies, pharmacoeconomic research, adverse reaction monitoring, and real-world research.
- Pharmacoeconomic Evaluation (药物经济学评价) Pharmacoeconomic evaluation services providing economic and benefit assessment of drugs, including evaluation scheme design, data analysis, report writing, and marketing support.
- Heyue Medical - Nuclear Medicine SMO (禾玥医药) SMO subsidiary focused on nuclear medicine clinical site management, providing professional field management and execution services for radiopharmaceutical clinical trials.
- Linddao Medical - Medical Device CRO (临道医疗) Medical device CRO subsidiary specializing in AI, medical aesthetics, cardiovascular, peripheral vascular, orthopedic, and ophthalmology device clinical research services, providing full-chain registration-to-clinical support.
Quantifiable outcome
- Served over 100 BE projects with high partner trust and recognition
- +1 more outcomes
Companies that use QuarkMed
Customer profileSegments7 records
Ideal customer profiles5 records
QuarkMed technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature3 records
QuarkMed partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- 禾玥医药 (Heyue Medical)core subsidiary禾玥医药成立于2017年，是夸克医药旗下专注于核药领域的专业SMO（临床试验现场管理组织），已稳健运营多年，持续为临床试验提供高质量的现场管理与执行服务。
Scale indicators3 records
Recent moves15 records
Expansion highlights2 records
QuarkMed competitors and assessment
Company assessmentDirect peers
- Hangzhou Tigermed (泰格医药): The largest China-domiciled clinical CRO, listed on HKEX and Shenzhen. Offers overlapping clinical operations, biostatistics, SMO, BE, and international registration services and competes head-on with QuarkMed for Chinese pharma and medical device sponsors.
- Frontage Holdings (方达医药): HKEX-listed clinical and bioanalytical CRO with strong BE and laboratory service offerings. Highly comparable to QuarkMed on bioequivalence, bioanalytical, and clinical operations work for Chinese generic and innovative sponsors.
- Genscript ProBio (金斯瑞蓬勃生物): CGT-focused CDMO/CRO providing plasmid, viral vector, and cell therapy development services. Direct competitor to QuarkMed's CGT clinical offering given the shared focus on Chinese cell and gene therapy sponsors.
- ICON plc: NASDAQ-listed global clinical CRO providing Phase I–IV operations, biostatistics, and laboratory services. Comparable to QuarkMed's clinical operations and international registration scope, with substantially larger scale.
- Syneos Health: Global clinical and commercial CRO (taken private by Elliott in 2023). Overlaps with QuarkMed on full-service clinical operations and cross-border registration work for biopharma sponsors.
- Parexel International: Privately held global clinical CRO (EQT/Goldman ownership) covering Phase I–IV operations, biostatistics, and regulatory services. Comparable to QuarkMed's international registration and full-lifecycle CRO model.
Broad incumbents
- WuXi AppTec (药明康德): Global CRO/CDMO leader listed on HKEX and Shanghai, providing end-to-end drug discovery, clinical, and manufacturing services. Competes with QuarkMed in clinical operations and bioanalytical services with substantially greater scale and brand recognition.
- Pharmaron (康龙化成): China-headquartered, HKEX/SZSE-listed CRO/CDMO with global laboratory, clinical, and manufacturing capabilities. Overlaps with QuarkMed on clinical operations, BE, and bioanalytical services and serves many of the same Chinese and international sponsors.
- Asymchem Laboratories (凯莱英): HKEX/SZSE-listed CDMO with growing clinical and biological services. Overlaps with QuarkMed in clinical operations for innovative drug sponsors and in BE-related bioanalytical work.
- Charles River Laboratories: NYSE-listed global CRO with preclinical, clinical, and manufacturing services. Comparable to QuarkMed at the broad CRO level, particularly on early-phase clinical operations and bioanalytical services.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
QuarkMed social profiles
Digital presenceQuarkMed financial estimates
Financial estimateRevenue estimate
Valuation estimate
QuarkMed leadership team
Management profileNumber of profiles
Profiles10 records
QuarkMed subsidiaries and ownership
Company hierarchySubsidiaries2 records
QuarkMed funding detail
Funding detailFunding overview
Funding rounds1 record
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
QuarkMed M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about QuarkMed
What does QuarkMed do?
QuarkMed is a clinical Contract Research Organization (CRO) providing full-service clinical research solutions for pharmaceutical and medical device companies. Services span the entire drug and device development lifecycle—from registration declaration and clinical operations through post-marketing research—covering therapeutic areas including nuclear medicine, oncology, cell and gene therapy (CGT), psychiatry/neurology, respiratory, medical devices, and bioequivalence, with international registration services for China, Europe, Australia, and North America markets.
Is QuarkMed a public or private company?
QuarkMed is a private company. It is classified as venture growth investor backed and is currently operating.
When was QuarkMed founded?
QuarkMed was founded in 2011. It employs 11 to 50 people.
Where is QuarkMed based?
QuarkMed is headquartered in Fengtai, China, in the Asia region.
How does QuarkMed make money?
One revenue line is on record: clinical CRO Service Fees.
Who are QuarkMed's main competitors?
Direct peers on record are Hangzhou Tigermed (泰格医药), Frontage Holdings (方达医药), Genscript ProBio (金斯瑞蓬勃生物), ICON plc, Syneos Health and Parexel International. Broad incumbents are WuXi AppTec (药明康德), Pharmaron (康龙化成), Asymchem Laboratories (凯莱英) and Charles River Laboratories.
Does QuarkMed have an API?
No public API is recorded for QuarkMed.
What industry is QuarkMed in?
QuarkMed's product category is Clinical Research Organization (CRO) Services. Its primary akta.pro industry code is HLAGAAAA, Clinical CROs (Phase I–IV), with a secondary code of HLAGAAAL, Specialty Therapeutic-Area CROs (e.g., oncology/rare disease). Its NAICS code is 54171 and its SIC code is 8731.